{"disease":{"id":"advanced-or-metastatic-urothelial-carcinoma-with-disease-progression-on-or-after-platinum-containing-chemotherapy-and-at-least-one-other-systemic-therapy-and-in-patients-who-are-not-eligible-for-platinum-containing-chemotherapy-and-in-patients-who-are-not-eligible-for-atezolizumab-plus-platinum-containing-chemotherapy-and-in-patients-who-are-not-eligible-for-pembrolizumab-plus-axitinib-and-in-patients-who-are-not-eligible-for-avelumab-plus-axitinib-and-in-patients-who-are-not-eligible-for-durvalumab-plus-tremelimumab.md","name":"advanced or metastatic urothelial carcinoma with disease progression on or after platinum containing chemotherapy and at least one other systemic therapy and in patients who are not eligible for platinum containing chemotherapy and in patients who are not eligible for atezolizumab plus platinum containing chemotherapy and in patients who are not eligible for pembrolizumab plus axitinib and in patients who are not eligible for avelumab plus axitinib and in patients who are not eligible for durvalumab plus tremelimumab.md"},"drugs":{"marketed":[],"pipeline":[],"offLabel":[],"totalMarketed":0,"totalPipeline":0},"trials":{"data":[],"total":0},"guidelines":[],"source":"Drug Landscape verified database"}